Cleared Traditional

K823256 - ULTRA-ASEPT ANGIOGRAPHIC SYRINGE/SPARE

K823256 is the FDA 510(k) clearance for ULTRA-ASEPT ANGIOGRAPHIC SYRINGE/SPARE by Vertex Medical Corp.. It is a Class 2 Cardiovascular device (product code DXT) cleared through the Traditional 510(k) pathway after a 59-day FDA review.

K823256 · Vertex Medical Corp. · Cardiovascular device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 1982
Decision
59d
Days
Class 2
Risk

K823256 is an FDA 510(k) clearance for the ULTRA-ASEPT ANGIOGRAPHIC SYRINGE/SPARE. Classified as Injector And Syringe, Angiographic (product code DXT), Class II - Special Controls.

Submitted by Vertex Medical Corp. (Walker, US). The FDA issued a Cleared decision on December 30, 1982 after a review of 59 days - a notably fast clearance cycle.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.1650 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Vertex Medical Corp. devices

Submission Details

510(k) Number K823256 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 01, 1982
Decision Date December 30, 1982
Days to Decision 59 days
Submission Type Traditional
Review Panel Cardiovascular (CV)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
66d faster than avg
Panel avg: 125d · This submission: 59d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code DXT Injector And Syringe, Angiographic
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 870.1650
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Cardiovascular devices follow this clearance model.

Regulatory Peers - DXT Injector And Syringe, Angiographic

All 102
Devices cleared under the same product code (DXT) and FDA review panel - the closest regulatory comparables to K823256.
ANGIOGRAPHIC DRAPE PACKS
K840281 · Medrad, Inc. · Apr 1984
ANGIOPLASTY INFLATION DEVICE & CARTR
K834107 · Cordis Corp. · Jan 1984
DIGITAL INJECTOR SYS
K833138 · Sybron Corp. · Nov 1983
MARK V
K822536 · Medrad, Inc. · Sep 1982
QUICK FILL
K800823 · Medrad, Inc. · Apr 1980
ANGIOPLASTY INJECTOR
K800613 · Medrad, Inc. · Apr 1980